Skip to content Skip to footer

What Do Peptides Do? Mechanism, Research Applications and Handling Requirements

What do peptides do in biological systems? They act as signalling molecules, hormones, neurotransmitters, enzyme substrates, antimicrobial agents and structural components. Peptides are short chains of amino acids joined by peptide bonds, and their sequence determines which receptors, enzymes or membranes they interact with. In the laboratory, researchers use synthetic peptides to study receptor binding, intracellular signalling, protease activity, immune recognition and protein folding. This article explains the functions of peptides at a molecular level, summarises the published literature, describes the main laboratory applications and sets out the purity, storage and handling standards expected in UK research settings. It concerns in-vitro work only.

What are peptides, and how were their functions discovered?

A peptide forms when the carboxyl group of one amino acid condenses with the amino group of another, releasing water and creating an amide linkage called a peptide bond. By convention, chains of up to roughly fifty residues are called peptides, and longer chains are called proteins, although the boundary is not rigid. Molecular weights for research peptides typically range from a few hundred to a few thousand daltons. Each is defined by its primary sequence, written from the N-terminus to the C-terminus, and by any modifications such as C-terminal amidation, N-terminal acetylation, cyclisation or non-natural residues.

The history of the field is largely a history of discovering what individual peptides do. In 1902, Bayliss and Starling described secretin, a signalling substance released from the intestine that triggers pancreatic secretion. It is often cited as the first hormone to be identified, and it was later characterised as a peptide. Insulin was isolated in the early 1920s, and Frederick Sanger determined its amino acid sequence in the 1950s, the first complete sequence of a protein. In 1953, Vincent du Vigneaud reported the synthesis of oxytocin, the first synthetic polypeptide hormone, which confirmed its proposed structure. In 1963, Bruce Merrifield introduced solid-phase peptide synthesis, which made routine laboratory production practical. In 1975, Hughes, Kosterlitz and colleagues reported the isolation of the enkephalins, two pentapeptides from brain tissue that bind opioid receptors, which showed that the nervous system produces its own peptide signals.

The answer to what peptides do therefore depends entirely on the sequence in question. A tripeptide such as glutathione functions in cellular redox chemistry, a nine-residue peptide such as oxytocin acts on a specific receptor, and a cationic sequence of twenty residues may disrupt bacterial membranes in culture. No single description fits the class.

Mechanism of action

Most signalling peptides act by binding to receptors on the surface of target cells. The largest group of receptors is the G protein-coupled receptor superfamily, which spans the membrane seven times. When a peptide ligand occupies the extracellular binding pocket, the receptor changes conformation and activates intracellular heterotrimeric G proteins. Depending on the receptor subtype, this may stimulate or inhibit adenylyl cyclase, change cyclic AMP concentrations or activate phospholipase C, which alters intracellular calcium and protein kinase activity. Other peptides act on receptor tyrosine kinases or cytokine receptors, triggering phosphorylation cascades that change gene expression.

Binding specificity depends on sequence, secondary structure and the three-dimensional arrangement of side chains. A single residue substitution can convert an agonist into an antagonist or shift selectivity between receptor subtypes, which is why structure-activity studies, in which residues are replaced systematically, are standard in peptide pharmacology.

A second group of peptides works without a classical receptor. Antimicrobial peptides are typically cationic and amphipathic, and in vitro they insert into negatively charged bacterial membranes and compromise their integrity. Other peptides act as competitive substrates or inhibitors of enzymes, occupying the active site of a protease or kinase. Cell-penetrating peptides cross membranes by mechanisms that are still debated, and are studied as carriers for other molecules.

Metabolic stability shapes how these mechanisms are studied. Native peptides are cleaved rapidly by exopeptidases and endopeptidases in biological matrices, so their effective half-lives are often short. Researchers use stabilised analogues, protease inhibitors or controlled incubation times to manage this. Because mechanism, selectivity and stability all depend on sequence, the behaviour of one peptide cannot safely be inferred from another.

What the research shows

The literature on peptide function is vast, and the following examples are landmark methodological and structural studies. They describe laboratory work and make no claim about effects in humans.

Sanger and colleagues characterised the amino acid sequences of insulin’s two chains in the early to mid 1950s, using chemical fragmentation and chromatographic analysis of purified material. The work showed that a protein has a defined, reproducible sequence, which underpins all later peptide research. The background is indexed in a PubMed search on insulin amino acid sequencing.

Hughes and colleagues reported in Nature in 1975 that extracts of brain tissue contained two closely related pentapeptides with potent activity at opioid receptors, which they identified in bioassays using isolated tissue preparations. The finding established that endogenous peptides can act as neurotransmitters or neuromodulators, and it opened a field of neuropeptide research. Related literature can be browsed through a PubMed search on enkephalin discovery.

Merrifield’s 1963 paper in the Journal of the American Chemical Society described solid-phase synthesis, in which a peptide is assembled stepwise on a polymer support and washed free of reagents between coupling cycles. The study demonstrated the approach with a model tetrapeptide and replaced laborious solution-phase purification. Its importance for this topic is practical, because it is why synthetic peptides can be made to order for functional studies.

A more recent open-access review, “Therapeutic peptides: current applications and future directions”, in Signal Transduction and Targeted Therapy, surveys peptide drug development, including limitations such as poor stability and rapid clearance and the chemical strategies used to address them. It is available through PubMed Central. Readers should treat it as an account of drug-development science and not as evidence that any laboratory reagent is appropriate for human use.

Where animal studies exist for individual peptides, they typically describe administration in murine or other rodent models under ethical approval, with outcomes measured as receptor occupancy, gene expression or tissue-level biomarkers. Their protocols are specific to each compound and study, and no figure from them should be read as guidance for any other setting.

Research applications

In the laboratory, the question of what peptides do is answered through a set of well-defined experimental uses. In receptor pharmacology, peptides serve as reference ligands in binding and functional assays on transfected cell lines. Competitive binding experiments use labelled and unlabelled peptides to calculate affinity constants, and concentration-response curves characterise potency and efficacy.

In enzymology, short synthetic sequences act as substrates and inhibitors for proteases and kinases. Fluorogenic substrates release a signal on cleavage, allowing reaction kinetics to be followed in real time, which supports enzyme characterisation and inhibitor screening. In immunology, peptide epitopes are used to stimulate or map T-cell responses in vitro. Overlapping peptide libraries that span a protein’s full sequence help identify which regions are recognised by antibodies or T-cell receptors.

In structural biology and biophysics, peptides serve as models for folding, secondary-structure formation and aggregation. Circular dichroism and nuclear magnetic resonance spectroscopy are widely applied to short sequences to observe helix and sheet formation under varying solvent conditions. In materials science and cell culture, self-assembling peptides form hydrogels and scaffolds, and cell-adhesion motifs are used to coat surfaces. Antimicrobial peptide research continues in parallel, examining membrane interactions and activity against bacterial cultures.

In analytical chemistry, well-characterised peptides are reference standards for developing liquid chromatography and mass spectrometry methods, including those used in proteomics. Across all of these applications, a result is only as reliable as the identity, purity and concentration of the starting material, so quality verification is a practical necessity.

Purity, storage and handling

Purity is verified principally by reversed-phase high-performance liquid chromatography with ultraviolet detection at 214 nm, where the peptide bond absorbs. The chromatogram shows the main product peak and any impurities, such as deletion sequences, truncated chains and incompletely deprotected products. Mass spectrometry confirms that the observed molecular mass matches the theoretical value, and the two techniques together establish identity and purity. A purity figure quoted without a chromatogram is difficult to verify independently.

A batch-specific certificate of analysis matters because synthesis is not perfectly reproducible. Yield, impurity profile, water content and counter-ion content, most often trifluoroacetate from the cleavage step, vary between production runs. Net peptide content is also lower than gross weight, commonly 60 to 90 per cent, which affects every molar calculation. Residual trifluoroacetate can itself influence cell viability in sensitive assays. A generic specification sheet cannot capture these differences, whereas a document tied to a lot number can.

Because degradation accelerates once a peptide is reconstituted, batch-level HPLC verification matters more here than with more stable reagents, and UK laboratories comparing suppliers on how to buy best peptides should expect a batch-specific certificate of analysis and lyophilised storage at −20 °C. Lyophilised powder is the most stable form, with −80 °C preferred for sequences prone to degradation or for long-term archives. Vials should reach room temperature in a desiccator before opening, so that condensation does not introduce moisture to the powder.

Light and oxygen are further concerns. Sequences containing tryptophan, tyrosine, methionine or cysteine are vulnerable to oxidation, and light can accelerate it, so amber vials or storage in the dark are sensible precautions. Asparagine and glutamine residues may deamidate over time, particularly in solution.

Stability falls sharply after reconstitution, because hydrolysis, oxidation, aggregation and adsorption to container surfaces all proceed more quickly in solution. Solvent choice depends on the sequence. Sterile water suits many short, charged peptides, dilute acetic acid often suits basic sequences, and hydrophobic sequences may need a small volume of an organic co-solvent before dilution. Stock solutions are best prepared in small single-use aliquots in low-binding tubes, frozen promptly and thawed once, since repeated freeze-thaw cycles promote aggregation. Short-term refrigeration at 2 to 8 °C is appropriate only for sequences known to be stable in solution.

Handling follows standard UK laboratory practice. The Control of Substances Hazardous to Health Regulations require a risk assessment covering the weighing of fine powders and the solvents used. Gloves, eye protection and a laboratory coat are the minimum, and weighing is best done in a ventilated enclosure. Each vial and aliquot should be labelled with the sequence, lot number, concentration, solvent and date of reconstitution, and waste should be disposed of according to institutional chemical-waste procedures.

Frequently asked questions

What do peptides do in the body?
Naturally occurring peptides act as hormones, neurotransmitters, antimicrobial agents and signalling molecules, usually by binding specific receptors. Function depends on the individual sequence. This describes biology, not laboratory reagents, and research-grade peptides have not been evaluated for human or veterinary use or for any effect in living organisms.

What do peptides do in laboratory research?
Researchers use them as receptor ligands, enzyme substrates and inhibitors, immunological epitopes, structural models and analytical standards. Each application depends on sequence, purity and accurate concentration. Results are only reliable when the identity of the material has been verified by HPLC and mass spectrometry against a batch-specific certificate of analysis.

What is the difference between a peptide and a protein?
The distinction is based on length. Chains of up to roughly fifty amino acids are usually called peptides, and longer chains are proteins, although the boundary is not strict. Proteins generally fold into stable tertiary structures, whereas many short peptides are flexible in solution and adopt defined shapes mainly on binding.

How are research peptides made?
Most are produced by solid-phase peptide synthesis, in which amino acids are added one at a time to a chain anchored on an insoluble resin. The chain is then cleaved from the resin, usually with trifluoroacetic acid, purified by reversed-phase HPLC and freeze-dried. The product is typically supplied as a trifluoroacetate salt.

Peptides are supplied for in-vitro laboratory research only. They are not for human or veterinary use, and nothing in this article should be read as guidance on administration, dosing or any effect in a living organism.

Leave a comment

99% Purity Guarantee
Trusted By Researchers
★★★★★
Celebrating 500,000 Orders
Third party verified